Back to resultsAnti-TNF Agents for the Treatment of Rheumatoid Arthritis
Primary Purpose
Rheumatoid Arthritis
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Etanercept
Adalimumab
Sponsored by
About this trial
This is an interventional treatment trial for Rheumatoid Arthritis focused on measuring tumor necrosis factor (TNF) blockade, inflammatory autoimmune disorder
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of RA*
- Disease duration as defined from the onset of symptoms of at least 3 months prior to study entry
- Active RA with DAS28 > 4.4, clinically requiring the addition of anti-TNF therapy
- Stable dose of MTX between 7.5 mg and 25 mg weekly for at least 8 weeks prior to study entry
- Able and willing to self-administer subcutaneous injections or have available qualified person(s) or caregiver to administer subcutaneous injections
- For females, agree to use accepted methods of contraception during the duration of the study and for 150 days after study completion*. *More information on these criterion can be found in the protocol.
Exclusion Criteria:
- Positive PPD test - a tuberculosis (TB) skin test: (> 5 mm induration regardless of prior Bacille Calmette-Guerin [BCG] vaccine administration) without evidence of ongoing treatment for at least 30 days or completed treatment
- History of positive PPD or chest x-ray findings indicative of prior TB infection, without documentation of either treatment for TB infection or chemoprophylaxis for TB exposure
- Prednisone dose > 10 mg/day (or equivalent dose of another corticosteroid) within 30 days prior to study entry
- Definitive diagnosis of another autoimmune disease that may require immunosuppression for treatment*
- Concomitant use of DMARDSs (e.g., disease-modifying antirheumatic drugs)*
- Any immunosuppressive therapy other than MTX, NSAIDs, or corticosteroids*
- Current or previous use of any biologic agent
- Presence of open leg ulcers
- Chronic or persistent infection that might be worsened by immunosuppressive treatment*
- Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to study entry
- Received oral antibiotics, antivirals, or antifungals within 14 days prior to study entry
- Certain abnormal laboratory values*
- Any medical condition that, in the opinion of the investigator, would interfere with the study
- History of malignancy other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma within 10 years prior to study entry
- Any Investigational agent within the earlier of 4 weeks or 5 half-lives prior to study entry
- History of drug or alcohol abuse within 6 months prior to study entry
- Known allergy or hypersensitivity to study products
- Inability or unwillingness to follow the protocol
- Any condition or treatment that, in the opinion of the investigator, places the participant at an unacceptable risk
- Pregnant or breastfeeding *More information on these criterion are in the protocol.
Sites / Locations
- University of Alabama
- University of California, San Francisco
- Yale University School Medicine
- University of Chicago
- Feinstein Institute for Medical Research
- University of Rochester
- Medical University of South Carolina
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Etanercept
Adalimumab
Arm Description
Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
Outcomes
Primary Outcome Measures
Percentage of CD27+ Switched Memory B Cells at Week 12
Analysis of the steady state composition of the B cell compartment were performed using ex-vivo multicolor flow cytometry on Ficoll isolated peripheral blood mononuclear cells (PBMCs). CD27+ switched memory B cells are a subset of B cells and are assessed by flow cytometry. CD27+ switched memory B cells are expressed as a percent of B cells. Lower CD27+ memory B cells indicate a decrease in the generation of B cell memory which may be caused by blocking lymphotoxin (LT) and tumor necrosis factor (TNF) signaling.
Secondary Outcome Measures
Percentage of Participants Fulfilling DAS-28-CRP "Good or Moderate Response" Criteria at Week 12
Good responders: change in DAS28-CRP (Baseline-Week12) > 1.2 and Week 12 DAS-CRP score was <\= 3.2. If the conditions for non-response* or good response were not met, the DAS28-CRP response was considered moderate. Participants with measurements for designated time points were included in the analysis. [*Non-responders had any of 4 conditions: change in DAS28-CRP (Baseline -Week 12) <0.6; 0.6 <\= change in DAS28-CRP ( Baseline-Week 12) < 1.2 with Week 12 DAS28-CRP score > 5.1; a flare that required prednisone > 10 mg/day (or equivalent) beyond Week 8 or the inability to taper prednisone to <\= 10 mg/day by Week 8; or the participant required prednisone > 20 mg/day at any time point].
Percentage of Participants Fulfilling DAS-28-CRP "Good or Moderate Response" Criteria at Week 24
Good responders had: change in DAS28-CRP (Baseline-Week 24) > 1.2 and the Week 24 DAS-CRP score was <= 3.2. If the conditions for non-response* or good response were not met then the DAS28-CRP response was considered moderate.[*Non-responders had any of the 4 conditions: change in DAS28-CRP (Baseline -Week 24) <0.6; 0.6 <\= change in DAS28-CRP ( Baseline-Week 24) < 1.2 with Week 24 DAS28-CRP score > 5.1 ; a flare that required prednisone > 10 mg/day (or equivalent) beyond Week 8 or the inability to taper prednisone to <= 10 mg/day by Week 8; or the participant required prednisone > 20 mg/day at any time point]. Participants with measurements for designated time points were included in the analysis.
Percentage of Participants Meeting ACR20 Response Criteria at Week 12
The American College of Rheumatology (ACR) 20 Responder Index is defined as someone who achieved at least 20% improvement in the tender and swollen 28-joint count, and 20% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Percentage of Participants Meeting ACR20 Response Criteria at Week 24
The American College of Rheumatology (ACR) 20 Responder Index is defined as someone who achieved at least 20% improvement in the tender and swollen 28-joint count, and 20% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Percentage of Participants Meeting ACR50 Response Criteria at Week 12
The American College of Rheumatology (ACR) 50 Responder Index is defined as someone who achieved at least 50% improvement in the tender and swollen 28-joint count, and 50% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Percentage of Participants Meeting ACR50 Response Criteria at Week 24
The American College of Rheumatology (ACR) 50 Responder Index is defined as someone who achieved at least 50% improvement in the tender and swollen 28-joint count, and 50% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Full Information
NCT ID
NCT00837434
First Posted
February 3, 2009
Last Updated
August 31, 2021
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00837434
Brief Title
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
Official Title
A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluate Mechanism of Action of Anti-TNF Agents in Rheumatoid Arthritis
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
March 2009 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Rheumatoid arthritis (RA) is a chronic disease that leads to inflammation and progressive joint damage. RA is a systemic inflammatory autoimmune disorder affecting almost 1% of the United States population. Current therapies target the immune system early in the disease process before joint damage occurs, and include drugs such as methotrexate (MTX) and tumor necrosis factor (TNF)-blocking agents. The primary purpose of this study is to determine the effectiveness of two TNF inhibitors, etanercept and adalimumab, on memory B lymphocytes (B-cells) in the peripheral blood of participants with RA.
Additionally, there are 4 optional sub-studies as part of the trial:
B-Cell Kinetic Sub-Study to look at changes in B-cell subsets over time and how quickly reductions in B-cell memory occur
Vaccine Response Sub-Study to assess B cell memory in response to immunization with hepatitis B,-hepatitis A, and diphtheria/tetanus vaccines, and to determine whether T-cell vaccine responses are altered with TNF blockade
Tonsil Biopsy Sub-Study to evaluate how TNF blockade affects memory B-cells in the tonsil dendritic cells and germinal cells
Synovial Biopsy Sub-Study to evaluate how TNF blockade affects changes in memory B-cells in lymphoid tissue.
Detailed Description
RA is characterized by persistent inflammation of peripheral joints, causing pain, stiffness, swelling and warmth. Over the past 10 years, advancements in biotechnology have revolutionized RA therapeutics with biologically-derived immunomodulating compounds. TNF-alpha inhibitors constitute the largest class of these new biologic therapies. The purpose of this study is to determine the effectiveness two TNF inhibitors, etanercept and adalimumab, on memory B lymphocytes (B-cells) in the peripheral blood of participants with RA.
This study will last 24 weeks. Participants will be randomized into one of two treatment groups. Participants in one group will receive a dose of etanercept once every week for 24 weeks. Participants in the other group will receive a dose of adalimumab once every 2 weeks for 24 weeks.
This study consists of seven study visits after randomization and will occur at study entry and Weeks 4, 8, 12, 16, 20 and 24. Blood collection will occur at all study visits. A written participant assessment, vital signs, and physical exam will occur at study entry and Weeks 12 and 24. Follow-up calls to assess safety are scheduled for Weeks 4, 8, 16, and 20.
Additionally, participants will be offered the opportunity to enter one of four sub-studies as mentioned in the brief summary above: B Cell Kinetic Sub-Study, Vaccine Response Sub-Study, Tonsil Biopsy Sub-Study, and Synovial Biopsy Sub-Study. More information on these sub-studies is in the protocol.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis
Keywords
tumor necrosis factor (TNF) blockade, inflammatory autoimmune disorder
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
63 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Etanercept
Arm Type
Experimental
Arm Description
Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
Arm Title
Adalimumab
Arm Type
Experimental
Arm Description
Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
Intervention Type
Drug
Intervention Name(s)
Etanercept
Other Intervention Name(s)
Enbrel®
Intervention Description
50 mg dose of etanercept by subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
Adalimumab
Other Intervention Name(s)
Humira®)
Intervention Description
40 mg dose of adalimumab by subcutaneous injection
Primary Outcome Measure Information:
Title
Percentage of CD27+ Switched Memory B Cells at Week 12
Description
Analysis of the steady state composition of the B cell compartment were performed using ex-vivo multicolor flow cytometry on Ficoll isolated peripheral blood mononuclear cells (PBMCs). CD27+ switched memory B cells are a subset of B cells and are assessed by flow cytometry. CD27+ switched memory B cells are expressed as a percent of B cells. Lower CD27+ memory B cells indicate a decrease in the generation of B cell memory which may be caused by blocking lymphotoxin (LT) and tumor necrosis factor (TNF) signaling.
Time Frame
Week 12
Secondary Outcome Measure Information:
Title
Percentage of Participants Fulfilling DAS-28-CRP "Good or Moderate Response" Criteria at Week 12
Description
Good responders: change in DAS28-CRP (Baseline-Week12) > 1.2 and Week 12 DAS-CRP score was <\= 3.2. If the conditions for non-response* or good response were not met, the DAS28-CRP response was considered moderate. Participants with measurements for designated time points were included in the analysis. [*Non-responders had any of 4 conditions: change in DAS28-CRP (Baseline -Week 12) <0.6; 0.6 <\= change in DAS28-CRP ( Baseline-Week 12) < 1.2 with Week 12 DAS28-CRP score > 5.1; a flare that required prednisone > 10 mg/day (or equivalent) beyond Week 8 or the inability to taper prednisone to <\= 10 mg/day by Week 8; or the participant required prednisone > 20 mg/day at any time point].
Time Frame
Week 12
Title
Percentage of Participants Fulfilling DAS-28-CRP "Good or Moderate Response" Criteria at Week 24
Description
Good responders had: change in DAS28-CRP (Baseline-Week 24) > 1.2 and the Week 24 DAS-CRP score was <= 3.2. If the conditions for non-response* or good response were not met then the DAS28-CRP response was considered moderate.[*Non-responders had any of the 4 conditions: change in DAS28-CRP (Baseline -Week 24) <0.6; 0.6 <\= change in DAS28-CRP ( Baseline-Week 24) < 1.2 with Week 24 DAS28-CRP score > 5.1 ; a flare that required prednisone > 10 mg/day (or equivalent) beyond Week 8 or the inability to taper prednisone to <= 10 mg/day by Week 8; or the participant required prednisone > 20 mg/day at any time point]. Participants with measurements for designated time points were included in the analysis.
Time Frame
Week 24
Title
Percentage of Participants Meeting ACR20 Response Criteria at Week 12
Description
The American College of Rheumatology (ACR) 20 Responder Index is defined as someone who achieved at least 20% improvement in the tender and swollen 28-joint count, and 20% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Time Frame
Week 12
Title
Percentage of Participants Meeting ACR20 Response Criteria at Week 24
Description
The American College of Rheumatology (ACR) 20 Responder Index is defined as someone who achieved at least 20% improvement in the tender and swollen 28-joint count, and 20% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Time Frame
Week 24
Title
Percentage of Participants Meeting ACR50 Response Criteria at Week 12
Description
The American College of Rheumatology (ACR) 50 Responder Index is defined as someone who achieved at least 50% improvement in the tender and swollen 28-joint count, and 50% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Time Frame
Week 12
Title
Percentage of Participants Meeting ACR50 Response Criteria at Week 24
Description
The American College of Rheumatology (ACR) 50 Responder Index is defined as someone who achieved at least 50% improvement in the tender and swollen 28-joint count, and 50% improvement in at least three of the following 5 measures:
Patient's pain assessment (Visual Analogue Scale (VAS) 100 mm)
Patient's global assessment of disease activity (VAS 100 mm)
Physician's global assessment of disease activity (VAS 100 mm)
Patient self-assessed disability (Health Assessment Questionnaire (HAQ) score)
Acute phase reactant (CRP).
Participants with measurements for designated time points were included in the analysis.
Time Frame
Week 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of RA*
Disease duration as defined from the onset of symptoms of at least 3 months prior to study entry
Active RA with DAS28 > 4.4, clinically requiring the addition of anti-TNF therapy
Stable dose of MTX between 7.5 mg and 25 mg weekly for at least 8 weeks prior to study entry
Able and willing to self-administer subcutaneous injections or have available qualified person(s) or caregiver to administer subcutaneous injections
For females, agree to use accepted methods of contraception during the duration of the study and for 150 days after study completion*. *More information on these criterion can be found in the protocol.
Exclusion Criteria:
Positive PPD test - a tuberculosis (TB) skin test: (> 5 mm induration regardless of prior Bacille Calmette-Guerin [BCG] vaccine administration) without evidence of ongoing treatment for at least 30 days or completed treatment
History of positive PPD or chest x-ray findings indicative of prior TB infection, without documentation of either treatment for TB infection or chemoprophylaxis for TB exposure
Prednisone dose > 10 mg/day (or equivalent dose of another corticosteroid) within 30 days prior to study entry
Definitive diagnosis of another autoimmune disease that may require immunosuppression for treatment*
Concomitant use of DMARDSs (e.g., disease-modifying antirheumatic drugs)*
Any immunosuppressive therapy other than MTX, NSAIDs, or corticosteroids*
Current or previous use of any biologic agent
Presence of open leg ulcers
Chronic or persistent infection that might be worsened by immunosuppressive treatment*
Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to study entry
Received oral antibiotics, antivirals, or antifungals within 14 days prior to study entry
Certain abnormal laboratory values*
Any medical condition that, in the opinion of the investigator, would interfere with the study
History of malignancy other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma within 10 years prior to study entry
Any Investigational agent within the earlier of 4 weeks or 5 half-lives prior to study entry
History of drug or alcohol abuse within 6 months prior to study entry
Known allergy or hypersensitivity to study products
Inability or unwillingness to follow the protocol
Any condition or treatment that, in the opinion of the investigator, places the participant at an unacceptable risk
Pregnant or breastfeeding *More information on these criterion are in the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer A. Anolik, MD, PhD
Organizational Affiliation
University of Rochester
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Inaki Sanz, MD
Organizational Affiliation
University of Rochester
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
R. John Looney, MD
Organizational Affiliation
University of Rochester
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Meggan Mackay, MD
Organizational Affiliation
The Feinstein Institute for Medical Research NS-LIJ Health System
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jeffrey Curtis, MD
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Yale University School Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Feinstein Institute for Medical Research
City
Manhasset
State/Province
New York
ZIP/Postal Code
11030
Country
United States
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD Sharing Time Frame
On average, within 24 months after database lock for the trial.
IPD Sharing Access Criteria
Open access.
IPD Sharing URL
https://www.immport.org/home
Citations:
PubMed Identifier
18937634
Citation
Bingham CO 3rd. Emerging therapeutics for rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2008;66(3):210-5.
Results Reference
background
PubMed Identifier
19149036
Citation
Otomo K, Koike T. [TNF inhibitors for treatment of rheumatoid arthritis]. Nihon Naika Gakkai Zasshi. 2008 Oct 10;97(10):2405-12. doi: 10.2169/naika.97.2405. No abstract available. Japanese.
Results Reference
background
PubMed Identifier
18677056
Citation
Soen S. [Daily practice using the guidelines for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis]. Clin Calcium. 2008 Aug;18(8):1169-75. Japanese.
Results Reference
background
PubMed Identifier
34347945
Citation
Meednu N, Barnard J, Callahan K, Coca A, Marston B, Thiele R, Tabechian D, Bolster M, Curtis J, Mackay M, Graf J, Keating R, Smith E, Boyle K, Keyes-Elstein L, Welch B, Goldmuntz E, Anolik JH. Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells. Arthritis Rheumatol. 2022 Feb;74(2):200-211. doi: 10.1002/art.41941. Epub 2021 Dec 27.
Results Reference
result
Links:
URL
https://www.niaid.nih.gov
Description
National Institute of Allergy and Infectious Diseases (NIAID)
URL
https://www.niaid.nih.gov/about/dait
Description
Division of Allergy, Immunology, and Transplantation (DAIT)
Available IPD and Supporting Information:
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY824
Available IPD/Information Identifier
SDY824
Available IPD/Information Comments
The Immunology Database and Analysis Portal (ImmPort) is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts. The portal includes available analysis tools for researchers.
Available IPD/Information Type
Study Protocol
Available IPD/Information URL
http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY824
Available IPD/Information Identifier
SDY824
Available IPD/Information Comments
ImmPort study identifier is SDY824.
Available IPD/Information Type
Study summary, -design, -adverse event(s), -summary of participant assessments, -medications, -demographics, -lab tests, -mechanistic assays, -study files et al.
Available IPD/Information URL
http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY824
Available IPD/Information Identifier
SDY824
Available IPD/Information Comments
ImmPort study identifier is SDY824.
Learn more about this trial
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
We'll reach out to this number within 24 hrs